# The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations

> **NCT07632170** · NA · NOT_YET_RECRUITING · sponsor: **Bing Han** · enrollment: 30 (estimated)

## Conditions studied

- Myeloid Tumors

## Interventions

- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT07632170
- **Lead sponsor:** Bing Han
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-01
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07632170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07632170, "The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 Mutations". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07632170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*